However, a retrospective study from the National Cancer Data Base (NCDB) including 8321 patients with lymph node metastatic breast cancer (cN1-2 stage) showed that LRRT improved OS in patients with hormone-receptor negative disease, and ypN0 after NACT (HR 0.65; 95% CI 0.48–0.88; P < 0.01) whereas no OS benefit was observed in the whole study cohort including patients with different breast cancer subtypes [28]. The gene discussed is NR4A1; the disease is breast carcinoma.